Stratagene Expects 7 Percent Rise in Q4 Revenues;
Licenses microRNA Sequences from Max Planck
 
Stratagene last week said that it expects fourth-quarter revenue to be around $24.7 million, or 7 percent better than last year’s pro forma revenue of $23 million for the same period.
 
The uptick came largely from sales of the company’s QPCR products and reagents, which were up 7 percent, and from allergy diagnostics products, which were up 23 percent, Stratagene said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.